Stock Price Quote

DR. LAL PATHLABS LTD.

NSE : LALPATHLABBSE : 539524ISIN CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse : Arvind Lal
BSE2961.9081.5 (+2.83 %)
PREV CLOSE ( ) 2880.40
OPEN PRICE ( ) 2885.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18865
TODAY'S LOW / HIGH ( )2885.30 2991.30
52 WK LOW / HIGH ( )2295.1 3645
NSE2963.7083.7 (+2.91 %)
PREV CLOSE( ) 2880.00
OPEN PRICE ( ) 2897.90
BID PRICE (QTY) 2963.70 (572)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 340023
TODAY'S LOW / HIGH( ) 2896.90 2992.00
52 WK LOW / HIGH ( )2293.55 3653.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-02 1995
Management Info
Arvind Lal - Chairman - Managing Director
Registered Office

Address Block E,Sector 18,Rohini,
New Delhi,
Delhi-110085

Phone 011-30258600

Email lalpathlabs@lalpathlabs.com

Website www.lalpathlabs.com

Registrars Details
MUFG Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE

NEWS

25Jun Dr. Lal PathLabs expands genomics capa
Dr. Lal PathLabs has expanded its genomics capabilities by adding Illumi..
25Jun Dr. Lal PathLabs informs about press r
Dr. Lal PathLabs has informed that it enclosed Press Release titled ‘Dr...
25Jun Dr. Lal PathLabs surges on expanding g
Dr. Lal PathLabs is currently trading at Rs. 2771.95, up by 31.85 points..
04Jun Dr. Lal PathLabs informs about BRSR
Pursuant to the provisions of Regulation 34(2)(f) of the SEBI (Listing O..
04Jun Dr. Lal PathLabs informs about annual
Pursuant to the provisions of Regulation 34 of the SEBI (Listing Obligat..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit14844973
Gross Profit 1449 6213
Operating Profit 18437770
Net Sales 577223516

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kovai Medical Center (BSE)
peergroup  6374.60 (3.14%)
M.Cap ( in Cr)6975.25
Metropolis Health. (BSE)
peergroup  2058.30 (10.37%)
M.Cap ( in Cr)10663.53
Global Health (BSE)
peergroup  1278.65 (4.91%)
M.Cap ( in Cr)34366.32
Thyrocare Tech. (BSE)
peergroup  1094.40 (2.67%)
M.Cap ( in Cr)5799.71
Vijaya Diagnostic (BSE)
peergroup  1019.85 (1.76%)
M.Cap ( in Cr)10472.55

Shareholding Pattern

NON-INSTITUTION 6.1%
PROMOTERS 53.91%
FI/BANKS/INSURANCE 2.75%
MUTUAL FUNDS/UTI 12.84%
GOVERNMENT 0%
FII 0%

About Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. was incorporated in the year 1995. Its today's share price is 2961.9. Its current market capitalisation stands at Rs 24813.47 Cr. In the latest quarter, company has reported Gross Sales of Rs. 23516.15 Cr and Total Income of Rs.24631.37 Cr. The company's management includes Gurinder Singh Kalra, Somya Satsangi, Rajit Mehta, Rohit Bhasin, Rahul Sharma, Arun Duggal, Archana Lal Erdmann, Vandana Lal, Arvind Lal, Vinay Gujral.

It is listed on the BSE with a BSE Code of 539524 , NSE with an NSE Symbol of LALPATHLAB and ISIN of INE600L01024. It's Registered office is at Block E,Sector 18,RohiniNew Delhi-110085, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, SR Batliboi & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.